Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
04:45pm, Thursday, 16'th May 2024
BENSALEM, Pa. , May 16, 2024 /PRNewswire/ -- Law Offices of Howard G.
NEW YORK , May 14, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022
NEW YORK--(BUSINESS WIRE)-- #Investigation--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of Cal
NEW ORLEANS , May 10, 2024 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 25, 2
SAN DIEGO--(BUSINESS WIRE)---- $AKRO #AKRO--Robbins LLP is Investigating Allegations Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding Viability and Efficacy of its Trial Drug Candidate.
AKRO Investors: Reminder - Important Deadline in Securities Fraud Class Action Lawsuit Akero Therapeutics, Inc.
08:28pm, Friday, 10'th May 2024
RADNOR, Pa. , May 10, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United Stat
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 25, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of in
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
07:00am, Friday, 10'th May 2024
-- Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 -- -- Phase 3 SYNCHRONY Histology and
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming June 25, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who pur
Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
07:00am, Wednesday, 08'th May 2024
SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious meta
NEW YORK , May 8, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed again
NEW YORK , May 7, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022
Upcoming Lead Plaintiff Deadline is June 25, 2024 NEW YORK , May 7, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein") announces that a federal securities class a
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who p
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Akero Therapeutics, Inc. (“Akero” or the �
